Redeye has made some positive revisions to our forecasts and valuation following an upbeat Q1 report.
Redeye once again sees an active quarter for IRRAS with several encouraging signs for its anticipate...
Redeye initiates coverage of Initiator Pharma, a Danish biotech company, primarily developing CNS-ta...
Beijer Alma redovisar ett mycket starkt andra kvartal.
Redeye thinks the Q2 report, together with the recently announced deals, gives confidence for invest...
Totala intäkter under Q2'21 uppgick till 17,8 mkr, en ökning med 77% jämfört med samma period föregå...
Senzime rapporterade en försäljning på 4,390 mkr i Q2'21, motsvarande en tillväxt på 279% y/y.
Q2’21 ARR SEK 57m, up 21.5% y-o-y Growth could ramp up in ’22e, driven by Litium 8 Fair value range ...
Redeye is now raising forecasts and valuation following the announced partner deal for cell phone ca...
Idag offentliggjorde Nischer Properties sin delårsrapport för andra kvartalet 2021.
Fellow Finance’s H1 revenue fell short of our expectations as a result of the business financing dri...
Inhalation Sciences, som utvecklar aerosolgenererings-systemet PreciseInhale, har haft det trögt me...
Redeye is now raising forecasts and valuation following the announced partner deal for cell phone cameras and a solid Q2 report.
Core business drives solid beat in Q2’21 Including Principal Investment projects lifts estimates EV/...
Write-downs (~DKK 22m) overshadow a great Q2 We expect a high ~4% adj.
Following the Q2 results, we have made minor estimate changes and reiterate our DCF-based share price range of SEK 81-101 per share.
Josab publicerade idag den 27 augusti sin delårsrapport för årets andra kvartal.
Recyctec publicerade idag den 27 augusti 2021 sin delårsrapport för årets andra kvartal.
Redeye comments on Cyxone’s Q2 report, that offered no surprises.
Cline Scientific publicerade idag den 27 augusti sin delårsrapport för årets andra kvartal.
Saniona Q2’21 released yesterday showed the company progressing according to plans, we therefore lea...
We give a brief comment on today's news from Alzecure's ACD856 Phase I study.
Redeye anser att QuiaPEG visar tecken på framsteg i såväl interna projekt som affärsutveckling.
Humble Group publicerade den 27 augusti 2021 sin delårsrapport för andra kvartalet 2021.
Q2 sales up 5% vs. ABGSCe Expecting lower sales in Q3 due to weak order intake 1.
Shortcut Media Group (”SMG” eller ”bolaget”) publicerade den 27 augusti 2021 sin delårsrapport för a...
Redeye views Calmarks Q2 report as undramatic, and commercialization of its tests seems to go as pla...
Newton Nordic AB (”Newton Nordic” eller ”Bolaget”) är ett teknikbolag som utvecklar och erbjuder specialiserade lösningar för stabilisering ...
Redeye comments on 2cureX’s Q2 2021 report, with the company continually taking required steps towar...
Nettoomsättningen i andra kvartalet uppgick till EUR 26,6m (28,0), vilket motsvarar en minskning med...
